Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

663 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
PTEN Loss-of-Function Alterations Are Associated With Intrinsic Resistance to BRAF Inhibitors in Metastatic Melanoma.
Catalanotti F, Cheng DT, Shoushtari AN, Johnson DB, Panageas KS, Momtaz P, Higham C, Won HH, Harding JJ, Merghoub T, Rosen N, Sosman JA, Berger MF, Chapman PB, Solit DB. Catalanotti F, et al. Among authors: johnson db. JCO Precis Oncol. 2017 Jun 23;1:PO.16.00054. doi: 10.1200/PO.16.00054. eCollection 2017. JCO Precis Oncol. 2017. PMID: 32913971 Free PMC article.
Polycomb repressor complex 2 suppresses interferon-responsive MHC-II expression in melanoma cells and is associated with anti-PD-1 resistance.
James JL, Taylor BC, Axelrod ML, Sun X, Guerin LN, Gonzalez-Ericsson PI, Wang Y, Sanchez V, Fahey CC, Sanders ME, Xu Y, Hodges E, Johnson DB, Balko JM. James JL, et al. Among authors: johnson db. J Immunother Cancer. 2023 Nov 20;11(11):e007736. doi: 10.1136/jitc-2023-007736. J Immunother Cancer. 2023. PMID: 38315170 Free PMC article.
Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy.
Shi H, Hugo W, Kong X, Hong A, Koya RC, Moriceau G, Chodon T, Guo R, Johnson DB, Dahlman KB, Kelley MC, Kefford RF, Chmielowski B, Glaspy JA, Sosman JA, van Baren N, Long GV, Ribas A, Lo RS. Shi H, et al. Among authors: johnson db. Cancer Discov. 2014 Jan;4(1):80-93. doi: 10.1158/2159-8290.CD-13-0642. Epub 2013 Nov 21. Cancer Discov. 2014. PMID: 24265155 Free PMC article.
Tunable-combinatorial mechanisms of acquired resistance limit the efficacy of BRAF/MEK cotargeting but result in melanoma drug addiction.
Moriceau G, Hugo W, Hong A, Shi H, Kong X, Yu CC, Koya RC, Samatar AA, Khanlou N, Braun J, Ruchalski K, Seifert H, Larkin J, Dahlman KB, Johnson DB, Algazi A, Sosman JA, Ribas A, Lo RS. Moriceau G, et al. Among authors: johnson db. Cancer Cell. 2015 Feb 9;27(2):240-56. doi: 10.1016/j.ccell.2014.11.018. Epub 2015 Jan 15. Cancer Cell. 2015. PMID: 25600339 Free PMC article.
Trametinib in the treatment of melanoma.
Thota R, Johnson DB, Sosman JA. Thota R, et al. Among authors: johnson db. Expert Opin Biol Ther. 2015 May;15(5):735-47. doi: 10.1517/14712598.2015.1026323. Epub 2015 Mar 26. Expert Opin Biol Ther. 2015. PMID: 25812921 Free PMC article. Review.
Emerging targeted therapies for melanoma.
Johnson DB, Pollack MH, Sosman JA. Johnson DB, et al. Expert Opin Emerg Drugs. 2016 Jun;21(2):195-207. doi: 10.1080/14728214.2016.1184644. Epub 2016 May 17. Expert Opin Emerg Drugs. 2016. PMID: 27148822 Review.
663 results